2025-10-20 - Analysis Report
Okay, here's the report on Eli Lilly and Co. (LLY), incorporating all the provided information and focusing on a concise, data-driven analysis:

**Eli Lilly and Co. (LLY) Stock Analysis**

Eli Lilly and Co. is a pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products worldwide.

**1. Performance Summary**

*   **Cumulative Return vs. S&P 500 (VOO):**
    *   LLY: 206.88%
    *   VOO: 97.05%
    *   Difference: 109.83%
    *   Relative Difference (based on historical range): 50.8% (Indicates a strong historical outperformance relative to VOO)

*   **Alpha, Beta, and Growth (Based on Provided Table):**

| Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B)  |
|------------|---------|--------|---------|--------|---------|
| 2015-2017  | 11.0%   | 76.1%  | -17.0%  | -0.0   | 75.7    |
| 2016-2018  | 39.0%   | 68.9%  | 24.0%   | -0.0   | 103.7   |
| 2017-2019  | 41.0%   | 68.9%  | 19.0%   | 0.4    | 117.8   |
| 2018-2020  | 34.0%   | 79.8%  | 10.0%   | 0.4    | 151.4   |
| 2019-2021  | 53.0%   | 79.8%  | 7.0%    | 0.5    | 247.6   |
| 2020-2022  | 64.0%   | 79.8%  | 65.0%   | 0.4    | 328.0   |
| 2021-2023  | 125.0%  | 78.9%  | 124.0%  | 0.2    | 522.6   |
| 2022-2024  | 134.0%  | 81.2%  | 113.0%  | 0.2    | 692.1   |
| 2023-2025  | 98.0%   | 83.5%  | 37.0%   | 0.2    | 719.7   |

*   **Analysis:** The CAGR shows increasing growth rates in recent years, alongside strong alpha generation, indicating significant outperformance. Beta values remain relatively low, suggesting that LLY's performance is not highly correlated with the broader market. MDD data shows how high volatility it has.

**2. Recent Stock Price Movements**

*   **Current Price:** 802.83
*   **Previous Close:** 819.38
*   **Change:** -2.02%
*   **Moving Averages:**
    *   5-day: 816.11
    *   20-day: 796.91
    *   60-day: 751.63

*   **Analysis:** The stock price has experienced a recent dip, closing lower than its previous close and below the 5-day moving average, although it remains above the 20-day and 60-day moving averages.

**3. Technical Indicators & Outlook**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment Recommended)
*   **RSI:** 68.48 (Approaching overbought territory)
*   **PPO:** -0.33
*   **Hybrid Signal:** Cash_79%_Sell (Suggesting a risk-off approach)
*   **20-Day Relative Difference Change:** -5.8 (Short-term downward trend in relative performance)
*   **Expected Return:** 129.4% (Long-term expected outperformance vs. S&P 500)

*   **Analysis:** The MRI suggests a low-risk environment, but the high RSI indicates that the stock might be overbought. The Hybrid Signal recommends reducing holdings. The recent price decrease of -2.02% and the negative change in the 20-day relative difference suggest a short-term bearish trend. Despite this, the expected return is highly optimistic for long-term investors.

**4. Recent News & Analyst Opinions**

*   **Key Headlines:**

    *   Positive mentions in long-term investment articles (Motley Fool).
    *   Analyst report on Elanco Animal Health Incorporated (potentially influencing sentiment).
    *   Coverage of market movements (Investor's Business Daily, Barrons.com).
    *   **Negative Impact:** Trump's pledge to cut obesity drug prices caused a stock dive (Investor's Business Daily, Wall Street Journal).

*   **Analyst Consensus:**

    *   Overall Rating: Buy (Mean = 1.79)
    *   Target Price: $891 (Average), High: $1190, Low: $650

*   **Analysis:** Recent news is mixed. Positive long-term outlook articles are countered by concerns about potential drug price cuts. Analyst consensus remains bullish, with a significant average target price above the current price.

**5. & 6. Earnings and Financial Information:**

| Quarter     | EPS  | Revenue    |
|-------------|------|------------|
| 2025-08-07  | 6.3  | 15.56 B$   |
| 2025-05-01  | 3.07 | 12.73 B$   |
| 2024-10-30  | 1.08 | 11.44 B$   |
| 2024-08-08  | 3.29 | 11.30 B$   |
| 2025-08-07  | 3.29 | 11.30 B$   |

*Analysis:* EPS is volatile and hard to see the trend and sales are constantly increasing.

**Financial Information:**

| Quarter      | Revenue   | Profit Margin | Equity    | ROE       |
|--------------|-----------|---------------|-----------|-----------|
| 2025-06-30   | $15.56B   | 84.27%        | $18.27B   | 30.98%    |
| 2025-03-31   | $12.73B   | 82.53%        | $15.76B   | 17.50%    |
| 2024-12-31   | $13.53B   | 82.24%        | $14.19B   | 31.07%    |
| 2024-09-30   | $11.44B   | 81.02%        | $14.24B   | 6.81%     |
| 2024-06-30   | $11.30B   | 80.80%        | $13.56B   | 21.88%    |

*Analysis:* Revenues and profit margins are consistently high and generally increasing. Equity is also growing. ROE is volatile.

**7. Overall Assessment**

LLY demonstrates strong historical outperformance and growth, driven by increasing revenues and high profit margins. Analyst consensus remains positive, with significant upside potential.

**However, several factors warrant caution:**

*   Recent price weakness and technical indicators suggest potential short-term downside.
*   Political risk (drug price regulation) is a real concern.
*   Hybrid signal indicates a time to take profits (cash out 79%).
*   Volatile ROE and EPS.

**Investment Recommendation:**

While LLY exhibits excellent long-term potential, the current situation suggests a need for caution. A conservative approach would be to reduce holdings as indicated by the Hybrid Signal, or to wait for a more favorable entry point after the current pullback. Investors should closely monitor news related to drug price regulations and competitor activity. Despite short-term concerns, the long-term expected return remains highly attractive for investors who can tolerate volatility.
